NCT04957290 - A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 25, 2021

Primary Completion Date

May 10, 2023

Study Completion Date

June 7, 2023

Conditions

Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Interventions

DRUG

NOX66

NOX66 800 mg daily (400 mg suppository twice daily \[BID\]).

DRUG

NOX66

NOX66 1200 mg daily (600 mg suppository BID).

DRUG

NOX66

NOX66 1600 mg daily (800 mg suppository BID).

DRUG

NOX66

NOX66 2400 mg daily (1200 mg suppository BID).

DRUG

NOX66

NOX66 RP2D

RADIATION

EBRT

The dose levels of EBRT will be either 8 Gy as a single fraction, or 20/25 Gy as 5 fractions given over 5 to 10 days.

Trial Locations (2)

The University of Texas - MD Anderson Cancer Center - Genitourinary (GU) Cancer Center, Houston

Beverly Hills Cancer Center, Beverly Hills